Literature DB >> 9157988

Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.

X Y Chu1, Y Kato, Y Sugiyama.   

Abstract

We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats. In this paper, the multiplicity of biliary excretion mechanisms for these four anionic compounds was investigated using isolated liver bile canalicular membrane vesicles (CMVs) obtained from Sprague Dawley rats. For the carboxylate form of CPT-11 and the lactone and carboxylate forms of SN38-Glu, ATP-dependent uptake consisted of both high- and low-affinity components in CMVs. Mutual inhibition studies with S-(2,4-dinitrophenyl)glutathione, a representative substrate for cMOAT, and the uptake study using CMVs from Eisai hyperbilirubinemic rats revealed that cMOAT is responsible for the biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN38-Glu, whereas the high-affinity component for CPT-11 and the low-affinity component for SN38-Glu, which are expressed in Eisai hyperbilirubinemic rats, are governed by a transporter different from cMOAT. The carboxylate form of SN-38 was found to be transported by cMOAT alone. We conclude that multiple transporters, including cMOAT, are responsible for the biliary excretion of CPT-11 and its metabolites (anionic forms), and the contribution of each transporter differs greatly, depending on the substrates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9157988

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Transfected rat cMOAT is functionally expressed on the apical membrane in Madin-Darby canine kidney (MDCK) cells.

Authors:  S Kinoshita; H Suzuki; K Ito; K Kume; T Shimizu; Y Sugiyama
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

2.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

3.  Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

Authors:  K Arimori; N Kuroki; A Kumamoto; N Tanoue; M Nakano; E Kumazawa; A Tohgo; M Kikuchi
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

4.  Paclitaxel-2'-Ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity.

Authors:  Tadatoshi Tanino; Akihiro Nawa; Eisaku Kondo; Fumitaka Kikkawa; Tohru Daikoku; Tatsuya Tsurumi; Chenhong Luo; Yukihiro Nishiyama; Yuki Takayanagi; Katuhiko Nishimori; Seiji Ichida; Tetsuyuki Wada; Yasuyoshi Miki; Masahiro Iwaki
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

5.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

Review 6.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

7.  Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.

Authors:  Wei Feng; Mavurapu Satyanarayana; Yuan-Chin Tsai; Angela A Liu; Leroy F Liu; Edmond J LaVoie
Journal:  Eur J Med Chem       Date:  2009-02-20       Impact factor: 6.514

8.  Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas.

Authors:  Takako Nakahara; Toshiyuki Sakaeda; Tsutomu Nakamura; Takao Tamura; Chiharu Nishioka; Nobuo Aoyama; Noboru Okamura; Toshiro Shirakawa; Akinobu Gotoh; Takashi Kamigaki; Masakazu Ohno; Yoshikazu Kuroda; Masafumi Matsuo; Masato Kasuga; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

9.  Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters.

Authors:  Xiao-Yan Chu; Yuexia Liang; Xiaoxin Cai; Karla Cuevas-Licea; Ronda K Rippley; Kelem Kassahun; Magang Shou; Matthew P Braun; George A Doss; M Reza Anari; Raymond Evers
Journal:  Pharm Res       Date:  2008-12-11       Impact factor: 4.200

10.  Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.

Authors:  Ken-ichi Fujita; Yusuke Masuo; Hidenori Okumura; Yusuke Watanabe; Hiromichi Suzuki; Yu Sunakawa; Ken Shimada; Kaori Kawara; Yuko Akiyama; Masanori Kitamura; Munetaka Kunishima; Yasutsuna Sasaki; Yukio Kato
Journal:  Pharm Res       Date:  2015-09-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.